Finch Therapeutics Group Inc.

2.74+0.0200+0.74%Vol 833.94K1Y Perf -83.24%
Jun 24th, 2022 16:00 DELAYED
BID2.72 ASK2.80
Open2.82 Previous Close2.72
Pre-Market- After-Market2.80
 - -  0.06 2.19%
Target Price
14.00 
Analyst Rating
Strong Buy 1.00
Potential %
410.95 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.12
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
6.56 
Earnings Rating
Market Cap130.31M 
Earnings Date
9th Aug 2022
Alpha-0.11 Standard Deviation0.20
Beta0.87 

Today's Price Range

2.672.90

52W Range

1.7117.39

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
4.58%
1 Month
35.64%
3 Months
-45.74%
6 Months
-74.61%
1 Year
-83.24%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FNCH2.740.02000.74
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.52-
Q04 2021-0.42-0.404.76
Q03 2021-0.42-0.2150.00
Q02 2021-0.28-0.32-14.29
Q01 2021-0.23-1.00-334.78
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.46
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume833.94K
Shares Outstanding47.56K
Shares Float26.63M
Trades Count2.03K
Dollar Volume2.29M
Avg. Volume428.33K
Avg. Weekly Volume197.67K
Avg. Monthly Volume114.16K
Avg. Quarterly Volume973.16K

Finch Therapeutics Group Inc. (NASDAQ: FNCH) stock closed at 2.74 per share at the end of the most recent trading day (a 0.74% change compared to the prior day closing price) with a volume of 833.94K shares and market capitalization of 130.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 131 people. Finch Therapeutics Group Inc. CEO is Mark Smith.

The one-year performance of Finch Therapeutics Group Inc. stock is -83.24%, while year-to-date (YTD) performance is -72.52%. FNCH stock has a five-year performance of %. Its 52-week range is between 1.7117 and 17.39, which gives FNCH stock a 52-week price range ratio of 6.56%

Finch Therapeutics Group Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 0.69, a price-to-sale (PS) ratio of 8.13, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.22%, a ROC of -32.13% and a ROE of -32.79%. The company’s profit margin is -%, its EBITDA margin is -439.10%, and its revenue ttm is $15.33 Million , which makes it $0.32 revenue per share.

Of the last four earnings reports from Finch Therapeutics Group Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Finch Therapeutics Group Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Finch Therapeutics Group Inc. is Strong Buy (1), with a target price of $14, which is +410.95% compared to the current price. The earnings rating for Finch Therapeutics Group Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Finch Therapeutics Group Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Finch Therapeutics Group Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 43.39, ATR14 : 0.29, CCI20 : 89.19, Chaikin Money Flow : -0.08, MACD : 0.02, Money Flow Index : 66.20, ROC : 7.87, RSI : 54.40, STOCH (14,3) : 60.61, STOCH RSI : 1.00, UO : 44.62, Williams %R : -39.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Finch Therapeutics Group Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Finch Therapeutics Group Inc.

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

CEO: Mark Smith

Telephone: +1 617 229-6499

Address: 200 Inner Belt Road, Somerville 02143, MA, US

Number of employees: 131

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

News

Stocktwits